Pharmacoepidemiologist working in drug-drug interaction safety research, focusing on opioids. My PhD dissertation used causal inference methods in tuberculosis survivor health, and I am extending that work into survivor health outcomes research more broadly. I have worked in a broad range of areas, including Indigenous health in Canada, tuberculosis, violent injury research, and multimorbidity. At ISPE I am doing a podium presentation on tramadol utilization in the United States over a 17-year study period, characterizing prescribers, patients, total amount dispensed, and state-specific trends in initiation and use of tramadol. Also presenting poster on oxycodone initiation during calcium channel blocker therapy, analyzing the relative risk of opioid overdose by CYP3A4-inhibiting CCBs (verapamil/diltiazem) compared with CYP3A4 non-inhibiting active comparator CCB (amlodipine). I am working towards a tenure-track position, and developing a K99 grant to advance my work in pharmacoepidemiology. I have a strong interest in diversity, equity, and inclusion (DEI), and the goal of pharmacoequity. Would be interested in hearing from other ISPE members who might be interested in developing new collaborations.